<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396043</url>
  </required_header>
  <id_info>
    <org_study_id>LBL-308</org_study_id>
    <nct_id>NCT02396043</nct_id>
  </id_info>
  <brief_title>Modified BFM-95 Regimen as First-Line Chemotherapy in Adults With T- Lymphoblastic Lymphoma</brief_title>
  <official_title>Modified BFM-95 Regimen for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults:a Prospective Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy and tolerability of treatment for T-lymphoblastic lymphoma&#xD;
      (T-LBL) according to modified BFM-95 regimen for acute lymphoblastic leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients received a modified BFM regimen which was derived from the NHL-BFM-95. The&#xD;
      differences were as follows: (1) during the course of high-dose methotrexate therapy&#xD;
      (HD-MTX), citrovorum folinate (CF) was used for rescue at 36 h after the administration of&#xD;
      HD-MTX;(2) Pirarubicin was used instead of daunorubicin (3) Pegaspargase was used instead of&#xD;
      L-asparaginase for patients.All patients received induction phase 1 and phase2, followed by&#xD;
      the protocol M, reinduction phase 1 and phase2, and maintenance (mercaptopurine 50 mg/m2&#xD;
      daily and methotrexate [MTX] 20 mg/m2 weekly, both orally) for up to a total therapy duration&#xD;
      of 24 months. CNS-positive patients received two additional doses of intrathecal MTX at days&#xD;
      18 and 27 of induction and received CRT after reinduction therapy. The dose was 18&#xD;
      Gy.Patients with identifiable blasts in CSF-cytospin preparation but less than 5cells/uL in&#xD;
      CSF were not considered CNS positive but received two additional doses of intrathecal MTX at&#xD;
      days 18 and 27. For men with testicular involvement,orchiectomy was not performed, and&#xD;
      irradiation (20 Gy) of testes was to be confined to biopsy-proven persistent infiltration of&#xD;
      testis after protocol M.Response to treatment was evaluated on day 33 and at the end of&#xD;
      induction in Modifed BFM-95.Sufficient response was defined as at least 70% tumor regression,&#xD;
      less than 5% BM blasts, and no CNS disease on day 33 and complete remission detected by PET /&#xD;
      CT at the end of induction.For patients with insufficient response at day 33 or at the end of&#xD;
      induction treatment was to be intensified according to the high-risk branch of trial&#xD;
      ALL-BFM95, with local radiotherapy (30 Gy) and allogeneic blood stem-cell transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">March 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 3 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>every 4 weeks,up to completion of induction treatment(approximately 2months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>up to end of follow-up-phase (approximately 3 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>safety, including hematological safety and non-hematological safety.All the adverse events will be classified according to Common Terminology Criteria for Adverse Events v3.0 (CTCAE)</measure>
    <time_frame>up to end of follow-up-phase (approximately 3 years)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Lymphoma, Lymphoblastic</condition>
  <arm_group>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients received induction phase 1 and phase2, followed by the protocol M, reinduction phase 1 and phase2, and maintenance (mercaptopurine 50 mg/m2 daily and methotrexate [MTX] 20 mg/m2 weekly, both orally) for up to a total therapy duration of 24 months. Response to treatment was evaluated on day 33 and at the end of induction in Modifed BFM-95.Sufficient response was defined as at least 70% tumor regression, less than 5% BM blasts, and no CNS disease on day 33 and complete remission detected by PET / CT at the end of induction.For patients with insufficient response at day 33 or at the end of induction treatment was to be intensified according to the high-risk branch of trial ALL-BFM95, with local radiotherapy (30 Gy) and allogeneic blood stem-cell transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction phase1</intervention_name>
    <description>Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.&#xD;
Pegaspargase :3750U/m2 im on days 8,22</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>Vincristine,Pirarubicin,Prednisone,Pegaspargase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>induction phase2</intervention_name>
    <description>Cyclophosphamide: 1000 mg/m2 iv on days 35, 59,Cytarabine: 75 mg/m2 iv on days 35-38, 42-45, 49-52, 56-59,Mercaptopurine: 60 mg/m2 po on days 35-59</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>Cyclophosphamide,Cytarabine,Mercaptopurine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>protocol M</intervention_name>
    <description>Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>Methotrexate,Mercaptopurine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maintenance therapy</intervention_name>
    <description>6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>6-mercaptopurine,Methotrexate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reinduction phase1</intervention_name>
    <description>Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.&#xD;
Pegaspargase :3750U/m2 im on days 8</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>Vincristine,Pirarubicin,Prednisone,Pegaspargase</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reinduction phase2</intervention_name>
    <description>Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>Cyclophosphamide,Cytarabine,Mercaptopurine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intrathecal (IT)</intervention_name>
    <description>methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38</description>
    <arm_group_label>Modifed BFM-95</arm_group_label>
    <other_name>methotrexate ,cytarabine and dexamethasone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  newly diagnosedT-LBL&#xD;
&#xD;
          -  age:18-65years&#xD;
&#xD;
          -  Ann Arbor stage IEto stage IVE&#xD;
&#xD;
          -  at lease one measurable lesion&#xD;
&#xD;
          -  receive no chemotherapy or radiotherapy before&#xD;
&#xD;
          -  Adequate renal function (eg, serum creatinine≤1.5 mg/dL and creatinine clearance ≥50&#xD;
             mL minute), and hepatic function (e.g, total bilirubin≤ 2 times the upper limit of&#xD;
             normal and aspartate and alanine transaminase levels ≤ 3 times the upper limit of&#xD;
             normal)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  mismatch the inclusion criteria&#xD;
&#xD;
          -  systematic central nervous system involvement, previous or concomitant malignancies&#xD;
             and any coexisting medical problems that could cause poor compliance with the study&#xD;
             protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hua Wang, MD.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Wang, MD.</last_name>
    <phone>0086-02087342438</phone>
    <email>wanghua@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>GuangZhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhongjun Xia, MD.</last_name>
      <phone>0086-02087342438</phone>
      <email>zhongjunxia_64@sina.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Wang K, Chen X, Wuxiao Z, Wang Z, Sun X, Zeng Z, Li S, Xia ZJ. Long-term outcomes of modified Berlin-Frankfurt-Münster-90 regimen in adults with T-lymphoblastic lymphoma: a single-center experience. Leuk Lymphoma. 2014 Aug;55(8):1800-5. doi: 10.3109/10428194.2013.828350. Epub 2014 Mar 7.</citation>
    <PMID>24475787</PMID>
  </results_reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 18, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>August 31, 2020</last_update_submitted>
  <last_update_submitted_qc>August 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>wanghua</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Mercaptopurine</mesh_term>
    <mesh_term>Pegaspargase</mesh_term>
    <mesh_term>Asparaginase</mesh_term>
    <mesh_term>Pirarubicin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

